Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 210 results:
Συντάκτης [ Τίτλος(Desc)] Τύπος Έτος
Φίλτρα: Συντάκτης is Athyros, Vasilios G  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
H
Athyros, V. G., & Mikhailidis D. P. (2016).  High incidence of metabolic syndrome further increases cardiovascular risk in patients with type 2 diabetes. Implications for everyday practice.. J Diabetes Complications. 30(1), 9-11.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2015).  High-intensity statin therapy and regression of coronary atherosclerosis in patients with diabetes mellitus.. J Diabetes Complications. 29(1), 142-5.
Katsiki, N., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2011).  Hyperuricaemia and non-alcoholic fatty liver disease (NAFLD): a relationship with implications for vascular risk?. Curr Vasc Pharmacol. 9(6), 698-705.
Katsiki, N., Doumas M., Athyros V. G., & Karagiannis A. (2015).  Hyperuricemia as a risk factor for cardiovascular disease.. Expert Rev Cardiovasc Ther. 13(1), 19-20.
I
Athyros, V. G., Mikhailidis D. P., Kakafika A. I., Karagiannis A., Hatzitolios A., Tziomalos K., et al. (2007).  Identifying and attaining LDL-C goals: mission accomplished? Next target: new therapeutic options to raise HDL-C levels.. Curr Drug Targets. 8(3), 483-8.
Athyros, V. G., Mitsiou E. K., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2010).  Impact of managing atherogenic dyslipidemia on cardiovascular outcome across different stages of diabetic nephropathy.. Expert Opin Pharmacother. 11(5), 723-30.
Athyros, V. G., Tziomalos K., Katsiki N., Gossios T. D., Giouleme O., Anagnostis P., et al. (2013).  The impact of smoking on cardiovascular outcomes and comorbidities in statin-treated patients with coronary artery disease: a post hoc analysis of the GREACE study.. Curr Vasc Pharmacol. 11(5), 779-84.
Anagnostis, P., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2011).  Impact of statins on glucose metabolism--a matter of debate.. Am J Cardiol. 107(12), 1866.
Karagiannis, A., Hatzitolios A. I., Athyros V. G., Deligianni K., Charalambous C., Papathanakis C., et al. (2009).  Implementation of guidelines for the management of arterial hypertension. The impulsion study.. Open Cardiovasc Med J. 3, 26-34.
Athyros, V. G., Hatzitolios A. I., Karagiannis A., Savopoulos C., Katsiki N., Tziomalos K., et al. (2011).  IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease rIsk factors by multifactorial interVEntion. The IMPERATIVE renal analysis.. Arch Med Sci. 7(6), 984-92.
J
Tziomalos, K., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2009).  JUPITER: major implications for vascular risk assessment.. Curr Med Res Opin. 25(1), 133-7.
Athyros, V. G., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2009).  The JUPITER trial results boost the evidence for the use of hsCRP as a treatment target and as part of the assessment of vascular risk: time for new guidelines?. Hellenic J Cardiol. 50(2), 89-91.
L
Didangelos, T. P., Arsos G. A., Karamitsos D. T., Athyros V. G., & Karatzas N. D. (2003).  Left ventricular systolic and diastolic function in normotensive type 1 diabetic patients with or without autonomic neuropathy: a radionuclide ventriculography study.. Diabetes Care. 26(7), 1955-60.
Tziomalos, K., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2012).  Lipid lowering agents and the endothelium: an update after 4 years.. Curr Vasc Pharmacol. 10(1), 33-41.
Athyros, V. G., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2010).  Lipid-lowering agents and new onset diabetes mellitus.. Expert Opin Pharmacother. 11(12), 1965-70.
Tziomalos, K., Athyros V. G., Wierzbicki A. S., & Mikhailidis D. P. (2009).  Lipoprotein a: where are we now?. Curr Opin Cardiol. 24(4), 351-7.
Theocharidou, E., Tellis C. C., Mavroudi M., Soufleris K., Gossios T. D., Giouleme O., et al. (2014).  Lipoprotein-associated phospholipase A2 and arterial stiffness evaluation in patients with inflammatory bowel diseases.. J Crohns Colitis. 8(9), 936-44.
Tessier, C. M., Polyzos S. A., Athyros V. G., & Mantzoros C. S. (2021).  Long-term statin treatment for hepatic fibrosis in patients with nonalcoholic fatty liver disease: Is it time to give the emperor a statin robe?. Metabolism. 121, 154796.
M
Tziomalos, K., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2010).  Management of statin-intolerant high-risk patients.. Curr Vasc Pharmacol. 8(5), 632-7.
Katsiki, N., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2012).  Managing the combination of non-alcoholic fatty liver disease and metabolic syndrome.. Expert Opin Pharmacother. 13(2), 287-8; author reply 289-90.
Kostapanos, M. S., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2012).  Mechanisms linking nonalcoholic fatty liver disease with coronary artery disease.. Dig Dis Sci. 57(4), 1109.
Karagiannis, A., Tziomalos K., Kakafika A. I., Athyros V. G., Harsoulis F., & Mikhailidis D. P. (2008).  Medical treatment as an alternative to adrenalectomy in patients with aldosterone-producing adenomas.. Endocr Relat Cancer. 15(3), 693-700.
Koumaras, C., Katsiki N., Athyros V. G., & Karagiannis A. (2013).  Metabolic syndrome and arterial stiffness: the past, the present and the future.. J Cardiovasc Med (Hagerstown). 14(10), 687-9.
Katsiki, N., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2014).  Metabolic syndrome and non-cardiac vascular diseases: an update from human studies.. Curr Pharm Des. 20(31), 4944-52.
Katsiki, N., Athyros V. G., & Karagiannis A. (2014).  Metabolic syndrome in clinical practice.. Cardiol J. 21(2), 209.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.

           

Σύνδεσμοι

 

Το πανεπιστήμιο

 
 

Προσωπικό & Φοιτητές